Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Crispr Therapeutics AG (CRSP)

NASDAQ
Currency in USD
Disclaimer
53.95
+0.22(+0.41%)
Real-time Data

CRSP Comments

Added 1100 shares
now u must be regretting
nope I'm long!
keep tanking this stock what a hopeless
Ouch
In few weaks 120
why are you so sure Mr. John Doe ? please ?
Possible. 102 is more likely. If it does approach 120, breaking 124 resistance will be a signifant upside challenge.
in 4 weeks 85
ouch. well since we're here.. i might as well average down
median bollinger band is broken on monthly TF... waiting the end of october...
97 usd  is a good entry point...
a classic Cathy wood collapse
how do you actually buy shares i have a buy sell window open but its an ad i wanna actually buy a stock not be sent to yet another bs broker app
Check if you Bank can help you out
Open and fund a brokerage account. There are many options.
wow
Beat on earnings!! Largly
Problem with this one is you're gonna need to wait a literal decade for it to be viable, regardless of studies/tests.
true
I think in a normal world… Definitely. My opinion, it right around the corner.
total bubble of cathie wollod pump
CRSP and AIRI are Good stockAIRI will go up to X3
keep on dropping...
good entry point is around 80
keep dropping, want to get back in
206 by Oct
That would be acceptable.
Last weekend, Intellia Therapeutics and Regeneron announced first-ever clinical data that support the safety and efficacy of in vivo CRISPR genome editing in humans. We summarise the findings here.
ride it to new highs
Alert: Crispr Therapeutics will acquire AGTC before end of FY2021 as a strategy to get into the ophthalmology space. Load up now & Stay tuned
ok, thanks
Thank you, but may we know your source, please?
What proof or source do you have that these facts have changed? See quote:  Gene therapy developer AGTC lost nearly half its market cap Thursday morning after Biogen exited a collaboration agreement on the heels of a big clinical failure. Interim six-month data on one of AGTC's investigational therapies showed it was generally safe but ineffective at treating a rare eye disorder known as X-linked retinoschisis (XLRS). The company plans to complete patient monitoring activities on the XLRS program but will not develop it further.
Held the dip, looks great
i think that someone knew the news about intellia on friday already and then bought Crispr quickly.
i thought the same.. lucky enough it was good news
ouch...shorts are about to get crushed
It will most likely go higher on monday due to good results from Intellia.
...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.